Looking Ahead in the Treatment of NSCLC
Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.
Implications of the VISION Trial for Clinical Practice
Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.
The VISION Trial
An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.
The Role of MET in NSCLC
A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.
NSCLC: Targeted Therapy Landscape
Paul K. Paik, MD, discusses currently available targeted therapies for patients with NSCLC.
Targetable Gene Alterations in NSCLC
An expert in non-small cell lung cancer describes targetable gene alterations and how these impact treatment selection.
Importance of Biomarker Testing in NSCLC
Paul K. Paik, MD, reviews the importance of biomarker testing and best practices in testing in patients with non-small cell lung cancer.
2 Commerce Drive Cranbury, NJ 08512